drugset / Trial / NCT06385847

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

NCT06385847

RandomizedCrossoverOpen-labelOther

Summary

The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in Patients of Prostate Cancer

Timeline

Start
2024-05
Primary completion
2025-05
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous
Subject LY01005 Unknown 3.6 mg Intramuscular

Indications